Focused On-demand Library for GTPase IMAP family member 5

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96F15

UPID:

GIMA5_HUMAN

Alternative names:

Immune-associated nucleotide-binding protein 5; Immunity-associated nucleotide 4-like 1 protein; Immunity-associated nucleotide 5 protein; Immunity-associated protein 3

Alternative UPACC:

Q96F15; D3DWZ5; Q6IA75; Q96NE4; Q9NUK9

Background:

GTPase IMAP family member 5, known by alternative names such as Immune-associated nucleotide-binding protein 5, plays a crucial role in T lymphocyte development, CD4/CD8 double-positive thymocytes generation, and GSK3A inhibition. It is pivotal in T cells proliferation, survival of peripheral T cells, NK and NK T-cell development, and liver function maintenance. Additionally, it regulates Ca(2+) homeostasis and mitochondrial DNA segregation in hematopoietic tissues.

Therapeutic significance:

Given its involvement in non-cirrhotic portal hypertension 2, a disorder characterized by portal hypertension without cirrhosis, understanding the role of GTPase IMAP family member 5 could open doors to potential therapeutic strategies for managing this condition and its complications, such as splenomegaly and esophageal varices.